GeneTether Therapeutics Inc. (GNTTF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry.
GNTTF has IPO date of 2022-10-14, listed on the Other OTC.
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin. Their platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.
